泼尼松龙联合酮咯酸与酮咯酸单药或筋膜下预防白内障术后黄斑增厚的随机临床试验
该单中心随机临床试验纳入470例低风险年龄相关性白内障行超声乳化术患者,比较五种抗炎预防方案对术后3个月黄斑中心厚度的影响。结果显示联合用药、单药及筋膜下地塞米松组间黄斑中心厚度和视力无显著差异,但筋膜下组过半需额外抗炎治疗,术前3天启动预防不优于手术当日启动。
要点
- 联合泼尼松龙与酮咯酸滴眼液在预防黄斑增厚方面不优于酮咯酸单药。
- 术前3天启动预防不优于手术当日启动。
- 筋膜下地塞米松组近六成患者需额外抗炎治疗。
核心结论
- 联合泼尼松龙与NSAID滴眼液与NSAID单药或筋膜下地塞米松相比,术后3个月黄斑中心厚度和视力无显著差异。
- 术前3天启动预防不优于手术当日启动。
- 无并发症白内障手术中可优先考虑NSAID单药治疗。
研究设计与样本
- 研究者发起的单中心随机临床试验,盲法统计分析,2018年2月1日至2019年8月15日在丹麦Glostrup的Rigshospitalet眼科招募患者。
- 纳入低风险年龄相关性白内障行超声乳化术患者(每人1眼),由经验丰富的外科医生手术,共470例(平均年龄72.2岁,女性290例占61.7%),每组94例。
主要发现
- 术后3个月平均黄斑中心厚度:术前泼尼松龙联合NSAID组250.7 μm(95%CI 247.6-253.7),术后联合组250.7 μm(95%CI 247.8-253.7),术前NSAID组251.3 μm(95%CI 248.2-254.4),术后NSAID组249.2 μm(95%CI 246.2-252.3),筋膜下组255.2 μm(95%CI 252.0-258.3)。
- 与对照组相比,黄斑中心厚度和视力无显著差异,术前与术后启动组间也无差异。
- 筋膜下组83例中有47例(56.6%)需要额外抗炎治疗。
关键数值与推荐
- 滴眼液每日3次,持续至术后3周。
- 主要结局为术后3个月黄斑中心厚度。
临床怎么用
- 无并发症白内障手术后可考虑NSAID单药预防黄斑增厚,无需常规联合泼尼松龙或筋膜下地塞米松。
- 术前启动预防并非必要,手术当日开始即可。
- 若选择筋膜下地塞米松,需注意超过半数患者可能需追加抗炎治疗。
局限性
- 单中心研究,纳入低风险患者且由经验丰富医生手术,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The choice of anti-inflammatory prophylaxis parallel to cataract surgery is important for patient safety and successful outcome of surgery, but which regimen to choose is contested. OBJECTIVES: To determine whether a combination of prednisolone and nonsteroidal anti-inflammatory drug (NSAID) eye drops was superior in preventing increased central macular thickness (central subfield thickness [CST]) after uncomplicated cataract surgery compared with NSAID monotherapy and sub-Tenon capsule depot (dropless surgery), and to test whether preoperative initiation of eye drop treatment was superior to initiation on the day of surgery. DESIGN, SETTING, AND PARTICIPANTS: This investigator-driven, single-center, randomized clinical trial with masked statistical analyses enrolled patients at the Department of Ophthalmology, Rigshospitalet Glostrup, Glostrup, Denmark, from February 1, 2018, to August 15, 2019. Follow-up was completed December 18, 2019. Participants included low-risk patients undergoing phacoemulsification for age-related cataract by an experienced surgeon (1 eye per participant). Data were analyzed from February 17 to June 15, 2020. INTERVENTIONS: Participants scheduled for cataract removal were randomized to 1 of 5 anti-inflammatory prophylactic regimens: eye drops with a combination of prednisolone, 1%, and ketorolac tromethamine, 0.5%, with or without preoperative initiation (preoperative prednisolone plus NSAID [control] and postoperative prednisolone plus NSAID groups), ketorolac monotherapy with or without preoperative initiation (preoperative and postoperative NSAID groups), or sub-Tenon depot of dexamethasone phosphate (sub-Tenon group). Eye drops were administered 3 times per day until 3 weeks postoperatively. MAIN OUTCOMES AND MEASURES: CST 3 months postoperatively. RESULTS: A total of 470 participants (mean [SD] age, 72.2 [7.0] years; 290 women [61.7%]) with 94 participants in each group were included in the analysis. Three months after surgery, the mean CST was 250.7 (95% CI, 247.6-253.7) μm in the preoperative prednisolone plus NSAID group, 250.7 (95% CI, 247.8-253.7) μm in the postoperative prednisolone plus NSAID group, 251.3 (95% CI, 248.2-254.4) μm in the preoperative NSAID group, 249.2 (95% CI, 246.2-252.3) μm in the postoperative NSAID group, and 255.2 (95% CI, 252.0-258.3) μm in the sub-Tenon group. There were no significant differences in CST or visual acuity compared with control and no differences between preoperative and postoperative groups, but 47 of 83 participants (56.6%) in the sub-Tenon group needed additional anti-inflammatory treatment. CONCLUSIONS AND RELEVANCE: No differences in CST or visual acuity were detected between the combination of prednisolone and NSAID eye drops vs NSAID monotherapy or sub-Tenon dexamethasone depot, although more than one-half of patients in the sub-Tenon arm received additional anti-inflammatory treatment. Initiating prophylaxis 3 days preoperatively was not superior to initiation on the day of surgery. Monotherapy with NSAIDs may be preferred in uncomplicated cataract surgery. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03383328.
引用
- Erichsen JH, Holm LM, Forslund Jacobsen M, et al. Prednisolone and Ketorolac vs Ketorolac Monotherapy or Sub-Tenon Prophylaxis for Macular Thickening in Cataract Surgery: A Randomized Clinical Trial. JAMA Ophthalmol. 2021. PMID: 34383010. doi:10.1001/jamaophthalmol.2021.2976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。